Implantable Monitor-Guided Anticoagulation for Non-Permanent Atrial Fibrillation

植入式监护仪引导抗凝治疗非永久性心房颤动

• 批准号: 8285045
• 负责人: ROD S PASSMAN
• 金额: $ 36.61万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-01 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8285045
• 关键词: Ablation; Address; Adverse event; Affect; Anticoagulants; Anticoagulation; Arrhythmia; Atrial Fibrillation; Cardiac; Cardiovascular system; Cessation of life; Chronic; Clinical Trials; Data; Devices; Disease; Dose; Enrollment; Event; Gastrointestinal Hemorrhage; Goals; Health; Health Personnel; Healthcare Systems; Heart failure; Hemorrhage; Home environment; Hospitalization; Hour; Incidence; Individual; Intervention; Intracranial Hemorrhages; Lead; Life; Methods; Minor; Modality; Monitor; Operative Surgical Procedures; Oral; Patients; Perception; Pharmaceutical Preparations; Pharmacology; Pharmacotherapy; Pilot Projects; Population; Public Health; Quality of life; Questionnaires; Recurrence; Risk; Risk Factors; SF-36; Sample Size; Sinus; Stroke; Stroke prevention; Technology; Thrombin; Thrombus; Time; Withdrawal; abstracting; base; cohort; compliance behavior; cost; data exchange; heart rhythm; improved; inhibitor/antagonist; insight; mortality; pill; premature; prevent; prospective; randomized trial; standard of care; subcutaneous; trial comparing

DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common sustained abnormal rhythm of the heart, affects an estimated 2.5 to 5 million individuals in the US, and can lead to stroke, heart failure, and premature death. For those with AF and other stroke risk factors, chronic anticoagulation is recommended to prevent intracardiac thrombus formation and stroke even if the AF is infrequent or short-lived. This standard of care is based partly on our inability to rapidly recognize and respond to AF recurrences which can often be brief and asymptomatic, but exposes the patient to the risk of anticoagulant-induced hemorrhage even during prolonged periods of sinus rhythm where the risk of stroke is presumably low. Recent advances in device technology and drug therapy, however, have the potential to change the way we manage AF. The use of a small leadless subcutaneous implantable cardiac monitor with remote data transmission capabilities (Reveal XT", Medtronic Inc.) provides the ability to remotely and continuously evaluate a patient for AF recurrences, even episodes that are brief and asymptomatic. In addition, the release of a unique oral thrombin inhibitor approved for use in non-valvular AF (Dabigatran [Pradaxa], Boehringer Ingelheim Inc.) allows for rapid onset anticoagulation within minutes to hours of a single oral dose. Together, these advances allow for continuous AF monitoring with targeted anticoagulation only around the time of an AF episode, thereby reducing the risk of drug-induced hemorrhage while still protecting against stroke. The aim of this pilot study is to assess the feasibility of intermittent anticoagulation wih dabigatran guided by continuous AF monitoring with Reveal XT" and remote data transmission to a healthcare provider. The study will enroll 75 AF patients from three centers with 1 or 2 other risk factors for stroke who have demonstrated persistent sinus rhythm following a rhythm control intervention which may include medications, ablation, or surgery. This pilot study will provide logistical insights, demonstrate feasibility, and generate required data for sample-size estimates for an anticipated large scale clinical trial comparing chronic anticoagulation with Reveal XT"-guided intermittent anticoagulation with dabigatran. This treatment modality can be anticipated to substantially reduce the exposure time to anticoagulation therapy, thereby reducing the risk of hemorrhage without increasing the risk of stroke. From a public health perspective, such a paradigm shift would reduce the cost of long-term anticoagulation, the impact of anticoagulant-related hemorrhage including the devastating consequences of intracranial hemorrhage, and improve quality of life in a portion of the millions of patients who already have AF and the 16 million expected to have the disease by the year 2050. If proven superior to current treatment methods this approach may improve a critical aspect of AF management and pave the way, along with advances in technology, for patient- directed in-home monitoring and treatment. PUBLIC HEALTH RELEVANCE: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with stroke, heart failure, premature death and significant cost to the healthcare system. Chronic anticoagulation, with its attendant risks of hemorrhage, is recommended for stroke prevention in patients with AF who also have other stroke risk factors, but may in fact only be necessary in the weeks surrounding an AF episode. This pilot study will assess the feasibility of treating patients with intermittent anticoagulation by using a new, rapid-onset oral thrombin inhibitor guided by an AF-sensing subcutaneous leadless implantable cardiac monitor with remote data transmission capabilities. If supported by a subsequent pivotal clinical trial, this paradigm shift could allow for reduced anticoagulation use, reduced hemorrhage risk, reduced cost and an improved quality of life with no increased risk of stroke in the ever-increasing AF population. (End of Abstract)

描述(由申请人提供)： 房颤(AF)是最常见的持续性心脏节律异常，在美国估计有250万至500万人受到影响，并可导致中风、心力衰竭和过早死亡。对于有房颤和其他中风危险因素的患者，推荐使用慢性抗凝来防止心内血栓的形成和中风，即使房颤很少发生或持续时间很短。这种标准的护理部分是基于我们无法快速识别和应对房颤的复发，房颤的复发通常是短暂的和无症状的，但即使在卒中风险较低的长时间窦性心律期间，患者也面临着抗凝剂诱导出血的风险。然而，设备技术和药物治疗的最新进展有可能改变我们处理房颤的方式。使用具有远程数据传输能力的小型无铅皮下植入式心脏监测器(Display XT“，Medtronic Inc.)提供远程和持续评估患者房颤复发的能力，即使是短暂和无症状的发作也是如此。此外，一种独特的口服凝血酶抑制剂的释放被批准用于非瓣膜性房颤(Dabigatran[Pradaxa]，Boehringer Inglheim Inc.)可在单次口服后数分钟至数小时内迅速起效抗凝作用。总而言之，这些进步使得只有在房颤发作前后才能通过靶向抗凝进行持续的房颤监测，从而降低了药物引起出血的风险，同时仍然可以预防中风。这项先导性研究的目的是评估Dabigatran间歇性抗凝的可行性，该方法是在持续房颤监测的指导下进行的，并将数据远程传输到医疗保健提供者。这项研究将从三个中心招募75名房颤患者，另有1到2名 经节律控制干预后出现持续性窦性心律的中风的危险因素，可能包括药物、消融或手术。这项先导性研究将提供后勤方面的见解，论证可行性，并为预期的大规模临床试验的样本量估计提供所需的数据，该试验将比较慢性抗凝与REVIDESS XT“引导的间歇性抗凝与达比加兰。可以预期，这种治疗方式可以显著减少接受抗凝治疗的时间，从而在不增加中风风险的情况下降低出血风险。从公共卫生的角度来看，这种范式的转变将降低长期抗凝的成本，降低抗凝剂相关出血的影响，包括颅内出血的破坏性后果，并改善数百万已经患有房颤的患者和预计到2050年将有1600万人患有房颤的患者的生活质量。如果证明优于目前的治疗方法，这种方法可能会改善房颤管理的一个关键方面，并随着技术的进步，为患者指导的家庭监测和治疗铺平道路。 公共卫生相关性： 房颤(房颤)是最常见的持续性心律失常，与中风、心力衰竭、过早死亡和医疗保健系统的巨额费用有关。对于有其他卒中危险因素的房颤患者，推荐使用慢性抗凝及其伴随的出血风险来预防中风，但实际上可能只在房颤发作周围的几周内才有必要。这项初步研究将评估在具有远程数据传输能力的房颤传感皮下无铅植入式心脏监测器的引导下，使用一种新型的快速起效的口服凝血酶抑制剂来治疗间歇性抗凝患者的可行性。如果得到随后的关键临床试验的支持，这种范式转变 在不断增加的房颤人群中，可以减少抗凝药物的使用，降低出血风险，降低成本，提高生活质量，而不会增加中风风险。 (摘要结束)